Pharmabiz4m
US FDA approves Novartis’ radioligand therapy, Lutathera for paediatric patients with gastroenteropancreatic neuroendocrine tumours
US FDA approves Novartis’ radioligand therapy, Lutathera for paediatric patients with gastroenteropancreatic neuroendocrine tumours: Basel Thursday, April 25, 2024, 15:00 Hrs [I ...
Pharmabiz1h
Regeneration Biomedical doses first patient in phase I trial of stem cell therapy to deliver directly to brain of Alzheimer’s disease patients
Newport Beach, California Thursday, April 25, 2024, 14:00 Hrs [IST] ...
Pharmabiz2h
US FDA grants accelerated approval to Day One Biopharma’s tovorafenib to treat relapsed or refractory BRAF-altered paediatric low-grade glioma
US FDA grants accelerated approval to Day One Biopharma’s tovorafenib to treat relapsed or refractory BRAF-altered paediatric low-grade glioma: Brisbane, California Thursday, Ap ...
Pharmabiz1h
SMBXL hosts India’s largest online B2B and B2C Hospital and Medical Supplies Expo
SMBXL hosts India’s largest online B2B and B2C Hospital and Medical Supplies Expo: Our Bureau, Mumbai Thursday, April 25, 2024, 13:30 Hrs [IST] SMBXL, a leading technology compa ...
Pharmabiz2h
United We Care partners with Adayu Mindfulness of Fortis Group to innovate mental well-being with AI
Our Bureau, Mumbai Thursday, April 25, 2024, 12:25 Hrs [IST] ...
Pharmabiz2h
Lupin Digital Health’s Lyfe platform receives Class C Medical Device license from CDSCO
Lupin Digital Health’s Lyfe platform receives Class C Medical Device license from CDSCO: Our Bureau, Mumbai Thursday, April 25, 2024, 12:10 Hrs [IST] Lupin Digital Health, India ...
Pharmabiz3h
Novartis, MMV announce positive data from phase II/III CALINA study of Coartem to treat babies 5 kg with malaria
Novartis, MMV announce positive data from phase II/III CALINA study of Coartem to treat babies 5 kg with malaria: Basel Thursday, April 25, 2024, 12:00 Hrs [IST] Novartis and Medi ...
Pharmabiz4h
EC grants label extension approval for Astellas’ Xtandi for use in additional recurrent early prostate cancer treatment setting
EC grants label extension approval for Astellas’ Xtandi for use in additional recurrent early prostate cancer treatment setting: Tokyo Thursday, April 25, 2024, 11:00 Hrs [IST] ...
Pharmabiz3h
King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, Hinduja Hospital & Hinduja Foundation establish health partners academy
King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, Hinduja Hospital & Hinduja Foundation establish health partners academy: Our Bureau, Mumbai Thursday, April ...
Pharmabiz5h
WHO Global Malaria Programme launches new operational strategy
The WHO Global Malaria Programme published a new operational strategy outlining its priorities and key activities up to 2030 to help change the trajectory of malaria trends, with a view to achieving ...
Pharmabiz7h
Ayush manufacturing industry grows six times in seven years: Ministry of Ayush
The Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa-Rigpa and Homoeopathy (Ayush) manufacturing industry in the country has registered around six times growth in seven years from the year 2014-15, ...
Pharmabiz7h
IIT Roorkee & UnivLabs tie up for commercialising technology related to ureteral stents
IIT Roorkee & UnivLabs tie up for commercialising technology related to ureteral stents: Our Bureau, New Delhi Thursday, April 25, 2024, 08:00 Hrs [IST] The Indian Institute of Te ...